[
    {
        "utterance": "Yan Jiao Zhou: skilled sequencing, which I think is our access to be large uh you know, to genome skilled sequencing not only just that ",
        "annotations": {
            "propose new idea": "The speaker introduces a new idea that skilled sequencing is their access to large genome sequencing, which hasn't been discussed before in the meeting."
        }
    },
    {
        "utterance": "Barbara Bendlin: I'm a neuroscientist by training but really more of an integrated biologist. I'm very interested in gut brain interactions in the context of cancer and specifically chemo. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own expertise and qualifications related to the task or topic area."
        }
    },
    {
        "utterance": "Mei Shen: and I use a lot of rodent models, but we also do some work in breast cancer patients. I'm Stephanie Clona. I'm at the University of Illinois at Chicago and I am trained as a mass spectrometrist. So my lab primarily does proteomic and lipidomic profiling and investigations to understand neurodegeneration and we actually work on a subset of disorders, lysosomal storage diseases that have neurodegenerative phenotypes. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own expertise as a mass spectrometrist and describes her lab's work, qualifying her background and research focus."
        }
    },
    {
        "utterance": "Barbara Bendlin: So I'm pretty excited to learn more about um really the interplay and that space and perhaps how our tools and our expertise can play a role. ",
        "annotations": {
            "signal expertise": "The utterance implies Barbara's expertise through mentioning 'our tools and our expertise', indicating her background and potential contributions.",
            "encourage participation": "By expressing interest in how their tools and expertise can play a role, Barbara implicitly encourages collaboration and participation."
        }
    },
    {
        "utterance": "Chris Whidbey: My training is in chemical biology and my group works on developing chemical tools and different omics techniques. ",
        "annotations": {
            "signal expertise": "Chris Whidbey explicitly states his training in chemical biology and his group's work, signaling his expertise in the field."
        }
    },
    {
        "utterance": "Michael Burton: I can go next. So my name is Michael Burton. I am a fourth year assistant professor at the University of Texas at Dallas. ",
        "annotations": {
            "process management": "Michael indicates his readiness to proceed with his introduction, managing the meeting flow.",
            "signal expertise": "Michael shares his professional background, signaling his expertise or qualifications."
        }
    },
    {
        "utterance": "Barbara Bendlin: She can't. ",
        "annotations": {
            "critical response": "The utterance 'She can't.' questions someone's ability, implying a negative evaluation."
        }
    },
    {
        "utterance": "Shikha Nangia: My name is Shikha Nangia from Syracuse University. I'm trained in computational physiology and behavior, so how the immune system affects the brain. My lab is focused on studying protein protein interactions in cell membranes, receptors, the blood brain barrier architecture, the tight junctions and also bacterial membranes. So we study influx of metabolites in and out of the bacterial membranes to whole body behaviors and metabolism metabolic functions. So I'm interested in understanding how metabolites and cells get inside through tight junctions or through the cell membranes themselves and in our context of feeding. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own expertise and qualifications related to the task, detailing her background in computational physiology and behavior, and her lab's focus areas."
        }
    },
    {
        "utterance": "Michael Burton: Thanks. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: Hi, I think that I may be an outlier here. ",
        "annotations": {
            "identify gap": "She explicitly states her potential difference from the group, implying a gap in her alignment or fit with the group."
        }
    },
    {
        "utterance": "Erin Longbrake: Hi, I think that I may be an outlier here. So I study multiple sclerosis and the uh microbiome as an immunomodulator if you will for autoimmune disease. And so I'm doing some studies of the microbiome but also wanted to include metabolomics as well. So interested in understanding a bit more. ",
        "annotations": {
            "identify gap": "Erin implies a gap in her knowledge or approach by expressing her interest in understanding more about metabolomics and possibly being an outlier."
        }
    },
    {
        "utterance": "Barbara Bendlin: Thanks Erin. I'm clinical translational too so clinical and chemical biologist. Um but we also have Angela from our CSA for reason sensors to um image the neurotransmitters in the brain. ",
        "annotations": {
            "acknowledge contribution": "The speaker verbally recognizes Erin, acknowledging her previous input.",
            "signal expertise": "The speaker explicitly states their own expertise and that of their team member Angela."
        }
    },
    {
        "utterance": "Barbara Bendlin: I think everybody is aware that we are in the metabolites and ions and small molecules. And we have some probing questions. So there's actually my call to the microbiome to choose a facilitator because we're going to download the slide deck and not facilitator, note taker I should say. ",
        "annotations": {
            "process management": "The speaker is managing meeting flow by discussing downloading the slide deck and clarifying roles.",
            "assign task": "The speaker assigns a task to the microbiome group to choose a facilitator."
        }
    },
    {
        "utterance": "Barbara Bendlin: Um and it's going to be the person who will report out to the larger group as well. Um do we have any volunteers? Does anybody want to take notes? ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by seeking a volunteer for note-taking.",
            "assign task": "The task of taking notes and reporting to the larger group is being assigned, with the speaker seeking a volunteer.",
            "encourage participation": "The speaker is inviting group members to contribute by volunteering for the note-taking task."
        }
    },
    {
        "utterance": "Chris Whidbey: Yes, I can. ",
        "annotations": {
            "process management": "Chris is volunteering for note-taking, which helps manage the meeting flow and organization."
        }
    },
    {
        "utterance": "Barbara Bendlin: Okay great thanks Chris. Do you have access to the um Google Drive folder? ",
        "annotations": {
            "ask question": "Barbara Bendlin is directly asking Chris Whidbey for information regarding his access to the Google Drive folder.",
            "process management": "By inquiring about Chris Whidbey's access to the Google Drive folder, Barbara Bendlin is managing the meeting's logistics and ensuring that tasks can be performed."
        }
    },
    {
        "utterance": "Chris Whidbey: Yes, I do. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: Fantastic. So my lab wrote some software that interprets the patient's behavioral state from the electrical signals recorded with the implanted devices. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her lab's capability and software development related to interpreting patient's behavioral state, which signals her expertise in the area."
        }
    },
    {
        "utterance": "Richard Wiener: You can take notes as you go along and put them in there or you can take notes on another screen and then transfer the important points in at the end whatever is convenient for you to do. ",
        "annotations": {
            "process management": "This code applies because Richard Wiener is providing instructions on how to manage note-taking during the meeting, which is a part of managing meeting flow and organization."
        }
    },
    {
        "utterance": "Chris Whidbey: I'm probably going to take notes by hand because I'm analog like that. ",
        "annotations": {
            "process management": "Chris is discussing how he plans to take notes during the meeting, which relates to managing the meeting process."
        }
    },
    {
        "utterance": "Richard Wiener: All right. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: Okay. There there's some panels at the bottom of my screen. Oh these these might be observers. ",
        "annotations": {
            "process management": "Barbara Bendlin is managing the meeting flow by pointing out the panels at the bottom of her screen and speculating about observers."
        }
    },
    {
        "utterance": "Richard Wiener: Those those folks are just observing the conversations you guys can get going on. ",
        "annotations": {
            "process management": "Richard is managing the meeting flow by informing the group about the presence of observers and encouraging them to continue their discussion."
        }
    },
    {
        "utterance": "Barbara Bendlin: Okay great. ",
        "annotations": {
            "None": "No relevant code applies to this utterance or it is too brief to apply any specific code."
        }
    },
    {
        "utterance": "Alda Ebrahimi: So my expertise we work on developing sensors and diagnostics to for example let's say if we know or we have some hypothesis and then we can work on building a sensor or a platform to monitor in real time. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own expertise related to developing sensors and diagnostics."
        }
    },
    {
        "utterance": "Richard Wiener: Oh yeah. ",
        "annotations": {
            "Supportive response": "The utterance 'Oh yeah.' expresses agreement or validation, which is a positive evaluation without adding new content."
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance in a substantial way."
        }
    },
    {
        "utterance": "Richard Wiener: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a minimal acknowledgment."
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code adds significant value beyond acknowledging that no detailed content is provided."
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it only contains a minimal acknowledgment."
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it only contains a minimal acknowledgment ('Okay.') without adding any substantial content to the discussion."
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code explicitly applies to this minimal utterance, but it could be seen as a form of acknowledgement or agreement."
        }
    },
    {
        "utterance": "Aida Ebrahimi: of the liver would be a very specific organ, you know, giving hormones, giving like the, on the same time they can look at the bile acids that are produced by the metabolic activity and they can measure the metabolic activity and the bacterial cells, they can measure their motion and their adhesion and their propagation in in in situ without needing to disrupt the nice cell of and also via inter interhepatic regulation. I don't know, circulation or enterohepatic circulation and that helps. So in an on this structure we can actually look at that, you know, lipids that could be produced by liver and then in turn fed to the microbiome. Who knows what happens to those um ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing concepts by elaborating how the liver interacts with the microbiome, including specifics about metabolic activity and lipid exchange."
        }
    },
    {
        "utterance": "Barbara Bendlin: So maybe rather, you know, maybe I know everybody's written something down, but perhaps we could do it this way. Um, are there, do you want to, does anybody want to comment on on Aida's observation or on any of these mechanisms? ",
        "annotations": {
            "ask question": "The utterance contains a clear question inviting others to comment on Aida's observation or any of the mechanisms discussed.",
            "encourage participation": "The utterance invites others to contribute their thoughts or comments.",
            "process management": "The speaker is managing the discussion flow by suggesting a way to proceed."
        }
    },
    {
        "utterance": "botB1: Would it be helpful if I just shared my screen so you could all see the notes I'm typing up while we go? ",
        "annotations": {
            "process management": "The speaker is suggesting a method to share information (notes) during the meeting, which directly relates to managing the meeting flow."
        }
    },
    {
        "utterance": "Barbara Bendlin: Sure. ",
        "annotations": {
            "supportive response": "The utterance 'Sure.' expresses agreement to a previous suggestion, which aligns with the definition of a supportive response."
        }
    },
    {
        "utterance": "botB1: Cool. ",
        "annotations": {
            "supportive response": "The utterance 'Cool.' expresses agreement or positivity towards the suggestion made by botB1 to share their screen.",
            "acknowledge contribution": "The utterance 'Cool.' acknowledges botB1's suggestion regarding sharing screens."
        }
    },
    {
        "utterance": "botB1: Thank you, that would be great. ",
        "annotations": {
            "Supportive response": "The speaker is expressing agreement and positivity towards the suggestion made by Barbara Bendlin, indicating a supportive response."
        }
    },
    {
        "utterance": "Yanjiao Zhou: So I think um the developing barrier as well as the membrane to the immune system. those are obviously related to once the bacteria are secreted the ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by mentioning the relationship between the developing barrier, membrane to the immune system, and bacteria secretion."
        }
    },
    {
        "utterance": "Aida Ebrahimi: No, no, no, they are secreted. So like in the extracellular solution. And these are in the so whatever they, so let's say they are metabolizing something, they uptake that thing and from the environment. So we can monitor the level of that. ",
        "annotations": {
            "develop idea": "The utterance expands on a previous idea by providing more details and clarification on the substances' behavior and location."
        }
    },
    {
        "utterance": "Barbara Bendlin: Can I just chime in and maybe this is a little bit of a naive question, but um as someone who ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it is more about prefacing a contribution to the discussion rather than engaging in the described interaction types."
        }
    },
    {
        "utterance": "Aida Ebrahimi: depending what it is because it can make a sensor if it is really if if it is permeable. That's the question. You know, kind of connection. But if they are, if their amount is changed in the extracellular metabolite solution. And because of these interactions, we can monitor ",
        "annotations": {
            "ask question": "The speaker asks a question about the conditions for creating a sensor.",
            "develop idea": "The speaker elaborates on the idea of monitoring changes in the extracellular metabolite solution.",
            "offer feedback": "The speaker provides conditional feedback on how something could work."
        }
    },
    {
        "utterance": "Barbara Bendlin: So if they continue like what ",
        "annotations": {
            "ask question": "The speaker is seeking clarification or further information about a previous statement or idea."
        }
    },
    {
        "utterance": "Aida Ebrahimi: what about other molecules? Is there if we know what they are. That's a big if. ",
        "annotations": {
            "ask question": "The utterance explicitly requests information or clarification about other molecules, fitting the definition of asking a question."
        }
    },
    {
        "utterance": "Yanjiao Zhou: maybe it is also related to the ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Aida Ebrahimi: if we need too much focus just on small molecules and not on biomarkers, you know, what are identifying what are those? So um I think maybe some of the, you know, maybe there is an overlap in terms of like the first question ",
        "annotations": {
            "develop idea": "The speaker is suggesting a connection between their current point about biomarkers and small molecules and a previous discussion."
        }
    },
    {
        "utterance": "botB1: What is a small molecule to me? Like a primary or secondary metabolite? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on what constitutes a small molecule, specifically wondering if it refers to primary or secondary metabolites."
        }
    },
    {
        "utterance": "Aida Ebrahimi: I think in some sense they are also, you know, we are talking about biomarkers. And maybe that's a definition issue amongst the field that I don't understand. Um, so for example, you know, when Bob was today talking about short fatty acids. So that's a biomarker. So let's say we can build a sensor to monitor the level of those. And ",
        "annotations": {
            "ask question": "The speaker is seeking clarification on the definition of terms like biomarkers within the field.",
            "develop idea": "The speaker is elaborating on the concept of biomarkers and potentially building on a previous idea about monitoring certain molecules.",
            "identify gap": "The speaker mentions a potential gap in their understanding, specifically about the definition of terms."
        }
    },
    {
        "utterance": "Ashley Ross: Hi. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Shikha Nangia: Sure. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a brief acknowledgment without additional substance."
        }
    },
    {
        "utterance": "Ashley Ross: Go ahead, Ashley. Um, immune cells, you know, peripheral immune factors. Um, you know, as you know, you know, there's been the recent discovery of the lymphatic system and how, you know, the lymphatic system acts as a conduit for a lot of these peripheral immune factors. ",
        "annotations": {
            "develop idea": "Ashley is expanding on the topic by sharing information about immune cells and the lymphatic system, adding more context to the discussion."
        }
    },
    {
        "utterance": "Aida Ebrahimi: That's a very interesting point. ",
        "annotations": {
            "supportive response": "The speaker is expressing a positive evaluation for another group member's contribution without adding new content."
        }
    },
    {
        "utterance": "Ashley Ross: And it's not just the the BBB in of itself, you know, there's been the recent discovery of the lymphatic system and how, you know, the lymphatic system acts as a conduit for a lot of these peripheral immune factors. Um, you know, as you know, you know, usually we think about the brain and microglia as intrinsic, you know, macrophage of the brain, but we also know that peripheral macrophages, uh, and T cells are also able to cross the BBB. Um, we don't really have the sensitivity to image the BBB except to say like, you know, if I had a giant gleoblastoma, we can tell you that it's ostensibly pretty leaky at that point. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by providing more information about the lymphatic system and its role in relation to the brain and immune factors.",
            "identify gap": "The speaker mentions a limitation in their ability to image the BBB, indicating a gap in current technology or methods."
        }
    },
    {
        "utterance": "Shikha Nangia: So I'd like to talk about the computational approach to all the things that have been discussed. I think that's I think what you're really hitting on is sort of the challenge question, right? Is it the short chain fatty acids we talk about ",
        "annotations": {
            "develop idea": "She is expanding on previous ideas by suggesting a computational approach.",
            "ask question": "She poses a question seeking clarification on what they are discussing."
        }
    },
    {
        "utterance": "Yanjiao Zhou: So does that continue like what conversation? In fact, there's a lot of traffic in the healthy state. is another transmitter that have a ",
        "annotations": {
            "ask question": "The speaker is seeking clarification or continuation of a previous discussion, indicating a request for more information."
        }
    },
    {
        "utterance": "Ashley Ross: Go ahead, Ashley. ",
        "annotations": {
            "encourage participation": "The speaker is inviting someone to contribute their thoughts or ideas, thereby encouraging participation in the conversation."
        }
    },
    {
        "utterance": "Ashley Ross: So my lab actually we've done electrochemical measuring norin, dopamine, serotonin, melatonin. And it's not just the the BBB in of itself, you know, there's been the recent discovery of the lymphatic system and how, you know, the lymphatic system acts as a conduit for a lot of these peripheral immune factors. Um, you know, as you know, you know, peripheral macrophages, uh, and T cells are also able to cross the BBB. Um, we don't really have the sensitivity to image the BBB except to say like, you know, if I had a giant gleoblastoma, we can tell you that it's ostensibly pretty leaky at that point. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by sharing specific research details and elaborating on the topic.",
            "signal expertise": "The speaker is explicitly stating their own expertise by mentioning their lab's work and research experience."
        }
    },
    {
        "utterance": "Shikha Nangia: But you know, to go back to Stephanie's point, you know, I think that's I think what you're really hitting on is sort of the challenge question, right? Is it the short chain fatty acids that are generated by the gut microbiota that just that drive a lot of these physiologic changes that we see. Or is it the intrinsic physiologic things that are mediated certain metabolites. Um, so I'm trying not to leave out trimethylamine oxide. And actually trimethylamine oxide is generated by uh FMO oxidation. So that's kind of getting to the sort of system. So if you know the walls of the two, you know, the epithelial cells and bacteria, but if you know the metabolites, the communication ",
        "annotations": {
            "Develop idea": "The speaker is expanding on existing ideas by posing a challenge question and providing additional examples.",
            "Ask question": "The utterance contains a question seeking clarification or further understanding of the ideas presented."
        }
    },
    {
        "utterance": "Shikha Nangia: And so, you know, there are these other sort of inflammatory cascades that Jay actually might know more about. And so, you know, there are these other sort of inflammatory cascades that Jay actually might know more about. And so, you know, there are these other sort of inflammatory cascades that Jay actually might know more about. And so, you know, there are these other sort of inflammatory cascades that Jay actually might know more about. ",
        "annotations": {
            "encourage participation": "The speaker invites Jay to contribute their expertise on inflammatory cascades, seeking their input or knowledge on the topic."
        }
    },
    {
        "utterance": "Yanjiao Zhou: Yeah, so you might have, we do have a lot of this paired data set. We have humoral, so any signaling pathways through the blood could be affected by cardiovascular health if not cardiovascular. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a previous topic by sharing their own data and insights, building upon existing ideas."
        }
    },
    {
        "utterance": "Shikha Nangia: Absolutely. I mean it's kind of like what we're talking about with the blood brain barrier, um how intact it is. ",
        "annotations": {
            "Supportive Response": "The speaker expresses agreement with a previous statement.",
            "Develop Idea": "The speaker expands on an existing idea by relating it to the blood-brain barrier."
        }
    },
    {
        "utterance": "Erin Longbrake: It does become important for access to the brain might impact how cognitive information, if you have a good clinical of your just the amount of heterogeneity that there is in the brain and this is one of the places where a lot of the existing microbiome and metabolome research falls short. I agree with you about the potential but I would say that part of the what we were thinking feeding into those models would be end up. Yeah, I think I mean as a mass spectrometrist, I think the biggest challenge and I don't do metabolomics, but the biggest challenge with it is is that um many metabolites have not been defined. ",
        "annotations": {
            "identify gap": "Erin Longbrake explicitly mentions that many metabolites have not been defined, highlighting a gap in knowledge.",
            "develop idea": "Erin expands on the challenges in metabolomics and its implications, building on existing ideas.",
            "supportive response": "Erin expresses agreement with previous statements, showing support for others' contributions."
        }
    },
    {
        "utterance": "Shikha Nangia: I agree with you that a successful pattern definition is a big data. And so untargeted is is really powerful because you can find a lot of signals that are changing but deducing that untargeted signal to a structure and understanding its function is really a bottleneck. We have to have detailed information to say this is what we need to cure this disease. I I I would echo that sort of. ",
        "annotations": {
            "supportive response": "The speaker agrees with a previous statement, showing support and validation for another group member's contribution.",
            "develop idea": "The speaker elaborates on the challenges of metabolomics, specifically about pattern definition and the role of untargeted approaches."
        }
    },
    {
        "utterance": "Shikha Nangia: And so yes, maybe the bottleneck is getting that big data right now because the tools so far to visualize are getting developed in other fields, not microbiota, but they will become available once we have the data. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a previously discussed idea about the challenges in microbiota research, specifically about the bottleneck of getting big data.",
            "identify gap": "The utterance explicitly mentions a gap in the current state of research, which is the availability of tools for visualization in microbiota research compared to other fields."
        }
    },
    {
        "utterance": "Flavio Frohlich: Um, so we we have done work with is um target panel. So that gets by and uh uh focusing on metabolites that are produced or co-produced. ",
        "annotations": {
            "develop idea": "The speaker is expanding on their previous work or ideas, specifically mentioning work with a target panel and focusing on certain metabolites.",
            "signal expertise": "The speaker is implicitly signaling their expertise by mentioning specific types of work they have done."
        }
    },
    {
        "utterance": "Shikha Nangia: I think in this question I identify. ",
        "annotations": {
            "acknowledge contribution": "The speaker verbally recognizes a point of connection or relation to a previous discussion or question.",
            "supportive response": "The speaker is expressing agreement or validation for the previous discussion."
        }
    },
    {
        "utterance": "Aida Ebrahimi: You know, it's you mentioned in other fields. For example, so we work a lot on material engineering and there are a lot of nanomaterials. So I know I personally don't work on energy for catalysis, but I know there are a lot of computational works that are starting from the first principle calculations and then coupling them with AI to really screen a bunch of different transition metal chalcogenides and chalcogenates to see how they interact with hydrogen and oxygen, very simple molecules to um for energy, for hydrogen evolution reaction or you know, basically for catalysis, you know, catalyzing those reactions. And then AI coupled with first principle calculations identify what are the type of defects or what transition metals that can actually be thermodynamic stable to make them and they are good to um for that application. And so then they guide the experimentalist that you know, don't build your material, molydenum disulfide for example with manganese. It is good, it is it is good for HER process for this catalytic process. And there has been a lot of discoveries actually that are like um again, I I I think in terms of the super conductivity that's also the same. They were actually started with computational results and they predicted that this is going to be like with a 1.1 degree for example you are going to get super conductivity. It started with and then people could do it. So you just focus on it. ",
        "annotations": {
            "propose new idea": "Aida introduces an example from material engineering, discussing the use of AI with first principle calculations.",
            "develop idea": "She elaborates on this idea by explaining its applications and how it works.",
            "signal expertise": "Aida mentions her work on material engineering, signaling her expertise in the field."
        }
    },
    {
        "utterance": "Flavio Frohlich: And um these restricted diets and the thing that I keep coming back to of very low levels of uh endogenous short chain fatty acid production like Dr. Brian was just talking about. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a topic previously discussed, specifically referencing Dr. Brian's comments on endogenous short chain fatty acid production.",
            "acknowledge contribution": "The speaker acknowledges Dr. Brian's previous comment by referencing it in their statement."
        }
    },
    {
        "utterance": "Barbara Bendlin: I was I was wondering if I could ask Claudia. ",
        "annotations": {
            "ask question": "Barbara Bendlin is requesting to ask Claudia a question, indicating she seeks information or clarification."
        }
    },
    {
        "utterance": "Aida Ebrahimi: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: I know you're busy taking notes but you can also comment and you know what when we get to 2 o'clock will work together to help you summarize and report out like it's not all going to be on you. I think we report out. ",
        "annotations": {
            "encourage participation": "Barbara Bendlin encourages Chris Whidbey to comment and participate in the discussion.",
            "process management": "Barbara Bendlin discusses how they will manage their work together, specifically note-taking and reporting out."
        }
    },
    {
        "utterance": "Chris Whidbey: Over connected. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Aida Ebrahimi: I guess. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey: And um these restricted diets the thing that I keep coming back to of very low levels of uh endogenous short chain fatty acid production like Dr. Brian was just talking about comes up in these types of conversations. And as it turns out is what allows to undergo snap meaning. ",
        "annotations": {
            "develop idea": "Chris is expanding on previous ideas discussed, specifically about restricted diets and short chain fatty acid production.",
            "supportive response": "Chris seems to be engaging with and supporting the direction of the conversation."
        }
    },
    {
        "utterance": "Barbara Bendlin: I was I was wondering if I could ask. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance"
        }
    },
    {
        "utterance": "Amina Schartup: No. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: Sarah, we've done some studies looking at the linings of the gut which are stimulated by which can be stimulated by the gut microbio to um computational models and how are you looking at the metabolites from the guts like and. ",
        "annotations": {
            "ask question": "The speaker is requesting information about others' approaches to studying metabolites from the gut."
        }
    },
    {
        "utterance": "Flavio Frohlich: That's a great question. This is a little bit outside of what we're doing so much but we're kind of starting to think about it. ",
        "annotations": {
            "acknowledge contribution": "Flavio Frohlich verbally recognizes another group member's input with a positive remark.",
            "identify gap": "Flavio Frohlich explicitly states that the topic is a little outside of their current focus, indicating a gap in their work."
        }
    },
    {
        "utterance": "Amina Schartup: I'm not doing any of that. I don't work with microbes. I wonder if that relates to the novelty, like the novel object responses that you see. So I'm interested. Like I said, I'm a trace metal chemist. I study mostly mercury cycling in the environment. And so the the reason I'm here is because I've been interested for a while in thinking about um gut microbiome. ",
        "annotations": {
            "identify gap": "Amina explicitly states her lack of work with microbes and her current interest in the gut microbiome, indicating a recognition of her own lack of expertise in the area.",
            "signal expertise": "Amina mentions her background as a trace metal chemist and her work on mercury cycling in the environment, which signals her expertise in that specific area."
        }
    },
    {
        "utterance": "Amina Schartup: I wonder if that relates to the novelty. ",
        "annotations": {
            "ask question": "Amina Schartup is requesting information or clarification on whether there's a relationship between certain phenomena and 'novelty'."
        }
    },
    {
        "utterance": "Amina Schartup: Um, not not not the novelty, so I'm I'm interested like I said, I'm a trace metal chemist. I study mostly mercury cycling in the environment. And so the the reason I'm here is because I've been interested for a while in thinking about um gut microbiome. What about the other direction? What about the brain to the gut? And so the question that I got from this morning is are those um you know, assets that are being produced are they there to support or are they certain molecules that are there to support a more varied and diverse system? And so the variety of the system is what I'm thinking about. That's really what I am interested in. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her background as a trace metal chemist.",
            "ask question": "The utterance contains a question about the direction of influence from the brain to the gut and the purpose of certain molecules.",
            "clarify goal": "The speaker is interested in understanding the system and its variety, relating to defining objectives."
        }
    },
    {
        "utterance": "Chris Whidbey: Right. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Mei Shen: I mean I'm pretty new to the field, right? I'm really learning. ",
        "annotations": {
            "identify gap": "Mei Shen explicitly recognizes her own lack of knowledge or experience in the field, indicating a gap in her understanding."
        }
    },
    {
        "utterance": "Yanjiao Zhou: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey: Of the gut. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Yanjiao Zhou: Of the gut. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey: Yes. ",
        "annotations": {
            "supportive response": "This is a supportive response as it indicates agreement with a previous statement."
        }
    },
    {
        "utterance": "Yanjiao Zhou: Yes. ",
        "annotations": {
            "None": "No relevant code applies to this utterance in a substantial way."
        }
    },
    {
        "utterance": "Mei Shen: So this is my last question was asking, right? How do they like specifically influence? I mean, I'm also curious about that like how many different kinds of bacteria in the gut. ",
        "annotations": {
            "ask question": "The speaker is requesting information about how certain factors specifically influence and about the number of different kinds of bacteria in the gut."
        }
    },
    {
        "utterance": "Chris Whidbey: Patients who often experience uh profound GI symptoms and and thought to have this. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey-Seattle University (he/him): this neurotype that restricts your diet doesn't allow you to test those already. I'm particularly interested in is it's like this autotoxic other metabolites, what other small molecules. So that's like one other way that the brain can the gut because they end up in that like, you know, that like half of it is unknown one unknown to unknown. ",
        "annotations": {
            "ask question": "The speaker is requesting information about specific metabolites and their interactions.",
            "develop idea": "The speaker is exploring and discussing existing concepts related to neurotypes, diet restrictions, and metabolite interactions."
        }
    },
    {
        "utterance": "Aida Ebrahimi (Penn State University): So another thing I think that would be interesting is how neuro not like gut brain axis place a super important role. So how I guess how these connections with agents when we're running but if it's unknown different kind of effects on those um. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new perspective on the importance of the neuro gut-brain axis.",
            "ask question": "The speaker asks for information about how connections with agents work and their effects.",
            "identify gap": "The speaker notes the unknown effects of neuro connections on various agents or aspects."
        }
    },
    {
        "utterance": "Chris Whidbey-Seattle University (he/him): the same is true for hypothetical genes in a metagenomics data set. The techniques are are getting better to get annotation and to describe particular genes. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by discussing the improvement of techniques for annotating and describing particular genes in metagenomics data sets."
        }
    },
    {
        "utterance": "Aida Ebrahimi (Penn State University): So there are all these students, but then what are the approaches actually to study these um, system level, so what's a common approach that people use for such kind of discoveries? ",
        "annotations": {
            "Ask Question": "The speaker is requesting information or clarification on approaches used for studying at a system level and for making discoveries."
        }
    },
    {
        "utterance": "Chris Whidbey-Seattle University (he/him): Some kind of maybe big data approach to identify those unknowns that are really important that you can then maybe use some computational spectra analysis. ",
        "annotations": {
            "propose new idea": "The speaker introduces a suggestion for using a big data approach and computational spectra analysis to identify unknowns.",
            "develop idea": "The suggestion expands on existing concepts to fit the specific research challenge discussed in the meeting."
        }
    },
    {
        "utterance": "Erin Longbrake - Yale: That's all. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin (she/her) University of Wisconsin-Madison: That does relate to the gut immune axis question as well, which is how, you know, how do we how do we identify those that are related to the gut that are being secreted by the microbiota. You need to perturb the system to then find those. ",
        "annotations": {
            "ask question": "The speaker is asking for information on how to identify substances related to the gut that are secreted by the microbiota.",
            "propose new idea": "The speaker suggests perturbing the system as an approach to find the substances in question."
        }
    },
    {
        "utterance": "Erin Longbrake - Yale: And and and I'll add to that that the gut is not as just uniform, you know, there's a lot of concern that we're looking at fecal microbiome that doesn't represent the local effects on the bacterial community itself and how that interacts with the host and you have effects on let's just say epithelial and endothelial cells. In terms of so to back to your question about what kind of approaches people sort of take to the system. you know, obviously there are many ways so so some of the approaches on nerve endings. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by providing more details and insights into the concerns and approaches related to studying the gut microbiome and its interactions.",
            "identify gap": "The speaker highlights a concern (or gap) in current research approaches, specifically the limitation of studying fecal microbiome.",
            "offer feedback": "The speaker provides insights that could be seen as feedback on approaches to studying the system."
        }
    },
    {
        "utterance": "Shikha Nangia (Syracuse University): Well, that gives me an idea for you have this discussion going on. So suppose I'm just going to hypothetically come up with an experiment. Uh, suppose we have mice which have no uh microbiota in it, like Baba showing initially. And then we say, okay, can we uh specific microbiota of say one or two species that we know, you know, bacterial species that we know. And I think that gives you an idea of where you have the discussion going on. So suppose I'm just going to hypothetically come up with an experiment. Uh, suppose we have mice which have no uh microbiota in it, like Baba showing initially. And then we say, okay, can we uh specific microbiota of say one or two species that we know, you know, bacterial species that we know. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new idea for a hypothetical experiment involving mice with no microbiota and the introduction of specific microbiota to study its effects."
        }
    },
    {
        "utterance": "Flavio Frohlich (he/him) - UNC: That's a great question. ",
        "annotations": {
            "Supportive Response": "Flavio Frohlich expresses agreement and positive evaluation for Shikha Nangia's hypothetical experiment proposal."
        }
    },
    {
        "utterance": "Shikha Nangia (Syracuse University): I agree with you. I guess that particular species of bacteria might help colonize. And then you can progressively increase the complexity of the microbiota that is introduced. And see how the metabolite uh big data approach. I know from other colleagues that I work with that there's synergy in some species with each other and there's one species that's more dominant. So if you start drawing those diagrams, when you have these two species overlapping each other, then you have the high dimensional system, things things actually work a little bit differently. So for example, you know, we train our neural nets for object recognition. ",
        "annotations": {
            "propose new idea": "The speaker suggests a hypothetical experiment involving introducing specific microbiota into mice.",
            "develop idea": "The speaker elaborates on the concept by discussing the complexity of microbiota and potential synergies between species.",
            "supportive response": "The utterance starts with 'I agree with you,' indicating agreement with a previous statement."
        }
    },
    {
        "utterance": "Erin Longbrake - Yale: In one case. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Shikha Nangia (Syracuse University): So hypothetically, you know, wild idea, but I think we need to grow that database of which particular species is responsible for a particular metabolite and then the interdependence because I'm sure one one kind of bacteria species is not going to be able to do that. So if you start drawing those diagrams, when you have these two species overlapping each other, then you have the high dimensional system, things things actually work a little bit differently. So for example, you know, we train our neural nets for object recognition. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new idea of creating a database to understand the relationship between specific bacteria species and metabolite production.",
            "develop idea": "The speaker elaborates on the idea by discussing the complexity of interactions between different bacteria species and how these interactions can lead to different outcomes."
        }
    },
    {
        "utterance": "Flavio Frohlich (he/him) - UNC: I'm just listening to all this and this is really amazing. ",
        "annotations": {
            "supportive response": "The speaker expresses a positive reaction to the discussion, indicating agreement or admiration without adding new content."
        }
    },
    {
        "utterance": "Mei Shen, University of Illinois at Urbana-Champaign: So so this is yeah, I I think is the idea millions of features but there are many steps you can take to really reduce the number of you know, feature selection but many of the features are highly correlated. So the network approach that there are many different ways to network approach. So I guess then you could link to the ",
        "annotations": {
            "develop idea": "Mei Shen is elaborating on existing concepts to approach the problem of dealing with millions of features and their correlations.",
            "offer feedback": "Mei Shen suggests using a network approach as a potential solution to handle the challenges of feature correlation."
        }
    },
    {
        "utterance": "Shikha Nangia (Syracuse University): I agree with you. I guess that particular species of bacteria might help colonize. And then you can progressively increase the complexity of the microbiota that is introduced. And see how the metabolite uh big data approach. I know from other colleagues that I work with that there's synergy in some species with each other and there's one species that's more dominant. So if you start drawing those diagrams, when you have these two species overlapping each other, then you have the high dimensional system, things things actually work a little bit differently. So for example, you know, we train our neural nets for object recognition. ",
        "annotations": {
            "Supportive response": "The speaker agrees with a previous statement.",
            "Develop idea": "The speaker expands on the idea of studying microbiota by suggesting a progressive increase in complexity and considering interactions between species.",
            "Propose new idea": "The speaker suggests a new approach to studying microbiota by introducing specific species and increasing complexity."
        }
    },
    {
        "utterance": "Flavio Frohlich (he/him) - UNC: So the problem with that then is you can't actually flip the problem on its head then and have model building too. ",
        "annotations": {
            "Critical response": "The speaker is pointing out a challenge or limitation with an approach.",
            "Identify gap": "The speaker highlights a potential problem or limitation with an approach, implying a gap in methodology or understanding."
        }
    },
    {
        "utterance": "Shikha Nangia (Syracuse University): I know it's good but this is what I'm hearing is there's a lot of experts will have to help in trying to sort of uh say, you know, what is the best way to proceed with that experiment but with the uh the limitation of just having so much. ",
        "annotations": {
            "identify gap": "The speaker recognizes the need for expert help, indicating a gap in their current knowledge or approach.",
            "process management": "The speaker is discussing how to proceed with an experiment, considering limitations and the need for expert input."
        }
    },
    {
        "utterance": "Flavio Frohlich: Uh and then next is uh individuals, we do next is kind of rank ordering uh to kind of map out the space of configurations. Because all those pathways, you say have 50 pathways, they're not all going to contribute to and understand how. Okay, how do we use statistical methods and biological prior knowledge to find the top three that could actually be linked to phenotype. And then that's when you start talking with biologists and then begging them to um to do like experimental validation. Um also something uh JP, you would know this like since you're in radiology, um you know, looking at brain images. I mean brain images of like maybe possibly areas of depending on what areas light up in a particular patient. I'm very new about how brain imaging works, but you know, people start have started you know, some of the recent Alzheimer's papers that I've just I've just reading just out of pure interest. I mean they do FM fMRI imaging and see what areas light up and does that have any statistical correlates with um you know, gut microbiome features or other features in the blood. ",
        "annotations": {
            "develop idea": "The speaker is discussing and elaborating on approaches to identify and validate biological pathways linked to phenotypes.",
            "ask question": "The speaker is seeking input from JP regarding brain imaging and its correlation with gut microbiome features.",
            "encourage participation": "The speaker invites JP to contribute their expertise in radiology."
        }
    },
    {
        "utterance": "Erin Longbrake: It's actually a couple years ago to that exact question. Um so what we did was we took mice, we transplanted um different gut microbial populations into them. So we had like like in four or five different groups and then we quantitatively imaged the brain. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on their experimental approach, describing how they conducted a study involving mice and gut microbial populations."
        }
    },
    {
        "utterance": "Shikha Nangia: So talking about what we just heard, what are the changes from young to old microbiome? That is the longitudinal study, which is what you just basically it's like large data set home and you just basically mash them together. So we did uh we did a K fold uh validation uh random forest supervised learning study. And we're able to show that you know, certain areas of the brain, there was structural change may actually say that's because we had this rosemary and we had this microstructural change over here and that's due to, you know, bifidobacterium in the gut. Which can make those statistical associations between gut microbial populations in the brain. The the problem with that as you know is these are pure statistical associations and actual biology is a little bit opaque. Like why do we see that? So it's hard to validate uh this sort of studies. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on a study about changes in the microbiome from young to old and its association with brain structural changes.",
            "summarize conversation": "The speaker summarizes a study on longitudinal changes in the microbiome and its association with brain structural changes."
        }
    },
    {
        "utterance": "Yanjiao Zhou: you know, people have done like longitudinal study and to say how. I mean, JP want to ask you a question. Uh you were talking about ranking these pathways in order that would be quite stable in the adults over time. What do you use to rank the pathways? Uh I think it's a challenge because there's so many ways to um you know, for example, there's many statistical ways to do this. I'll take the example of uh you know, gut microbiome data that people are looking into. So there are ways to do some type of permutation analysis, an over analysis. There's various statistical ways to kind of see what variance in particular microbial contributes most to uh the the clinical end point you have in mind. So let's say you have uh I'll just go back to my point earlier. Let's say you have like a thousand microbes. Yeah, you could kind of bin them down to particular principle components. Um which I'm sure many in the audience are familiar with that. And then see which principle components um correlates the most with uh with the clinical phenotype that you have. There's various statistical ways to do that. ",
        "annotations": {
            "ask question": "The speaker asks a question about what methods are used to rank pathways.",
            "summarize conversation": "The speaker summarizes some challenges and potential methods for ranking pathways in the context of gut microbiome data analysis."
        }
    },
    {
        "utterance": "Erin Longbrake: It also that it will be very useful to have a dictionary in that area. Where are the dominant bacteria and metabolites that are produced by those bacteria. ",
        "annotations": {
            "propose new idea": "Erin suggests the utility of having a dictionary that identifies dominant bacteria and metabolites produced by those bacteria, proposing a new approach or tool for their research.",
            "ask question": "Erin asks for information about the existence or location of a dictionary that could identify dominant bacteria and metabolites produced by those bacteria."
        }
    },
    {
        "utterance": "Chris Whidbey: I I part of the reason I asked the question is we've done some work with uh that's good information. But uh some of you already know. ",
        "annotations": {
            "signal expertise": "The speaker mentions having done work in the area, indicating expertise."
        }
    },
    {
        "utterance": "Erin Longbrake: So, uh I don't know, you know, sort of a dictionary like that. There are people that have been contributing more. ",
        "annotations": {
            "acknowledge contribution": "Erin acknowledges that there are people contributing more to the effort or a similar resource.",
            "identify gap": "Erin suggests a useful resource (a dictionary) could be helpful, indicating a perceived gap in current resources."
        }
    },
    {
        "utterance": "Yanjiao Zhou: Yeah, there are definitely established for those who haven't contributed as much. ",
        "annotations": {
            "offer feedback": "The speaker provides a general comment that can be seen as feedback on the state of contributions.",
            "critical response": "The utterance implies a critique by distinguishing between those who have contributed and those who haven't."
        }
    },
    {
        "utterance": "Ashley Ross: I'm wondering. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Yanjiao Zhou: Oh, I'm thinking about like a global. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey: Anyone else? ",
        "annotations": {
            "ask question": "Chris Whidbey is requesting information or contributions from others.",
            "encourage participation": "Chris Whidbey is inviting others to contribute to the discussion."
        }
    },
    {
        "utterance": "Ashley Ross: I I'm wondering, you know, there's been a lot of work done I was just just doing a pub med search on on organ on a chip, right? I'm wondering like do we should we reduce it, right? If we really want to understand the the role of reproductive microbiome, like should we make like a you know, reproductive system on a chip, you know, an ovary, a fallopian tube and the and understand the bacterial organ communication. I don't know, maybe I'm those I know we have my colleague who's on here, he's in lab. I don't know much about details, so yeah. ",
        "annotations": {
            "propose new idea": "explanation: Ashley Ross introduces a new idea of creating a 'reproductive system on a chip' to understand the role of reproductive microbiome.",
            "ask question": "explanation: The utterance contains questions about the approach to understanding the reproductive microbiome.",
            "supportive response": "explanation: The tone of the message seems to be inquiring and somewhat suggestive rather than critical, indicating a supportive or open discussion."
        }
    },
    {
        "utterance": "Mei Shen: I don't think you are. I I do agree that we have to do is is to focus on. ",
        "annotations": {
            "supportive response": "The speaker expresses agreement with an idea.",
            "critical response": "The speaker seems to disagree or be uncertain about a preceding statement."
        }
    },
    {
        "utterance": "Flavio Frohlich: That's that's an interesting question at least in psychiatry is that we have to do is to take the images and predict when the neuron is going to spike. So you take the the data of the image and the spikes uh train your own net to to predict when the neuron is going to spike. And then once you do that, we can invert that process. So we can synthesize a bunch of images that are predicted to drive high firing rates in the neuron. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Flavio Frohlich: So I wonder if if a sort of data driven scheme like that of taking microbiome observations predicting the disease pathologies and then inverting those predictors might also help in this case. Uh similar to where we can be relatively sure I assume that for a given disease label or diagnosis there are organ systems common biological alteration or pathology. ",
        "annotations": {
            "propose new idea": "The speaker introduces a novel approach of applying data-driven schemes to microbiome observations for predicting disease pathologies.",
            "develop idea": "The speaker elaborates on this idea by providing an analogy related to brain imaging and neuron firing rates."
        }
    },
    {
        "utterance": "Amina Schartup: I guess I kind of have a question following up on that. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification based on prior statements.",
            "acknowledge contribution": "The speaker is verbally recognizing a prior point or contribution to the discussion."
        }
    },
    {
        "utterance": "Chris Whidbey: I neurobiology is not my not my background at all. Are there how how good are the models? Are there ways to do like high. ",
        "annotations": {
            "identify gap": "The speaker explicitly states that neurobiology is not their background, indicating a lack of expertise in the area.",
            "ask question": "The speaker asks for information about how good models are and if there are ways to do something like 'high', requesting clarification or expertise from others."
        }
    },
    {
        "utterance": "Flavio Frohlich: Did I get anything? ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey: Yeah, I mean, I I think um uh to to to to to the point about um like using um I I think well let me just speak to a couple of things I've heard. Uh try to reduce uh the complexity to I don't know how that to um so that the the the classic reductionist approach to isolate that which we're trying to to test the hypothesis. Um but then when we study the gut microbiome and the human. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement and engaging with the discussion."
        }
    },
    {
        "utterance": "Flavio Frohlich: There are several people that are doing that. That's that's an interesting point. That's more an approach to common biological alteration or pathology. An important approach. ",
        "annotations": {
            "supportive response": "The speaker expresses agreement and positive evaluation for another group member's approach to common biological alteration or pathology."
        }
    },
    {
        "utterance": "Barbara Bendlin: Yeah, I mean for I can just comment on Alzheimer's disease and having known pathological features. So now we have people biomarkers that we can use and then leveraging useful reference databases to figure out what those metabolites are. Um but as Aaron mentioned humans are very heterogeneous and medications and what people are eating and there's a lot of overlap. So you also have to really well define the disease phenotype. ",
        "annotations": {
            "clarify goal": "The speaker emphasizes the need to well-define the disease phenotype, which is about defining objectives for studying Alzheimer's disease.",
            "develop idea": "The speaker builds upon previous discussion by highlighting challenges in studying Alzheimer's disease, such as human heterogeneity and the importance of biomarkers."
        }
    },
    {
        "utterance": "Barbara Bendlin: So so so I think I think from my perspective it's always been a challenge in um try to ",
        "annotations": {
            "identify gap": "The speaker mentions a challenge from her perspective, implying a gap or difficulty."
        }
    },
    {
        "utterance": "Erin Longbrake: neuro hypothesis likewise I'm friend of this complexity in humans that we don't have a lot of well defined biomarkers to follow with the clinical diagnosis. You know, so some some some approaches sort of try to interrogate many different systems that may be talking to each other and give us some signals to to to show that um this is indeed a biological condition. I think neurological conditions overall are heterogeneous and are complicated that have clearly defined and black and white. Not sure I'm going to answer just sort of throw out my my take on the the complexity especially at a system level. ",
        "annotations": {
            "identify gap": "Erin explicitly mentions the lack of well-defined biomarkers for clinical diagnosis.",
            "develop idea": "She expands on the challenges of neurological conditions, specifically about biomarkers and heterogeneity.",
            "clarify goal": "Discusses challenges in achieving clear clinical diagnoses."
        }
    },
    {
        "utterance": "Flavio Frohlich: Yeah, and then on the most frustrating kind of aspect for me is how stable are these microbiome like within a person like if you look at it longitudinally, do they change very rapidly? Yeah, there's a lot of study being done on this on this um throughout lifespan and typically as we understand it, um microbiome is quite dynamic up till age three or four um and then has a fairly stable um uh ",
        "annotations": {
            "ask question": "The speaker is requesting information about the stability of the microbiome within a person over time."
        }
    },
    {
        "utterance": "Barbara Bendlin: So for the ideal world, you know, if you had a traumatic perturbation whether it's antibiotics or um you know, traveler's diarrhea for example, those are kind of uh uh but short of these ",
        "annotations": {
            "clarify goal": "Barbara Bendlin is defining a scenario for discussion, possibly aiming to clarify objectives or set a context for understanding the impact of perturbations on the gut microbiome."
        }
    },
    {
        "utterance": "Flavio Frohlich: Yeah, thanks thanks for asking this. So the adult I would probably go back to school observation, right? And start there for example, antibiotics have a um I guess that would kind of depend on what level of taxonomic range we're looking at at the file level or ",
        "annotations": {
            "None": "No relevant code explicitly applies to this utterance"
        }
    },
    {
        "utterance": "Flavio Frohlich: So you know we know I think I would go for something like that, right? Where we have a perturbation that we know has a clear effect on the microbiome because I think of course the the universal there's no universal definition of strain but at the strain level it's actually pretty I would say dynamic and chaotic. ",
        "annotations": {
            "clarify goal": "The speaker is discussing the challenges in studying the microbiome, which relates to clarifying the goals and objectives of such studies, specifically highlighting the complexity of defining strains and the dynamic nature of the microbiome."
        }
    },
    {
        "utterance": "Flavio Frohlich: Yeah, and we know that that that that's indeed an area of psychiatric behavioral phenotypes that are transient and related to it. I don't know whether really that mechanism is um but that's probably where I start. And that wouldn't care about, you know, these people don't have any diagnosis so you avoid all that complexity of depression really is but you can assess ",
        "annotations": {
            "develop idea": "Flavio is expanding on existing ideas or concepts related to psychiatric behavioral phenotypes.",
            "ask question": "Flavio indirectly asks a question about the mechanism of psychiatric behavioral phenotypes.",
            "supportive response": "Flavio expresses a positive view towards studying psychiatric behavioral phenotypes."
        }
    },
    {
        "utterance": "Flavio Frohlich: Jeff Gordon at Washu has published a lot of research about the temporal dynamics and the sort of the overall stability of the microbiome and Jay is absolutely right it really depends on what level of taxonomic analysis we're doing this at. So um ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by referencing specific research and discussing the complexity of microbiome analysis.",
            "acknowledge contribution": "The speaker is recognizing the work of Jeff Gordon and aligning with a point made by Jay, thereby acknowledging contributions to the discussion."
        }
    },
    {
        "utterance": "Barbara Bendlin: So that works fine. if you're okay transcribing our our the question of like what does not affect the ",
        "annotations": {
            "process management": "The speaker is discussing the logistics of transcribing their conversation, which involves managing the group's workflow or activities."
        }
    },
    {
        "utterance": "Chris Whidbey: I'm opening it all. Um ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: So then to Wingen's question is like I think there's two major questions from that. One is how much significance do we assign for more more specific phylogenetic ",
        "annotations": {
            "develop idea": "The speaker is building upon a previous question by outlining two major questions, thereby expanding the discussion.",
            "clarify goal": "The discussion aims to clarify the objectives or approaches related to assigning significance to specific phylogenetic information."
        }
    },
    {
        "utterance": "Erin Longbrake: I like Flavio's idea though. ",
        "annotations": {
            "Supportive Response": "Erin Longbrake expresses agreement with Flavio Frohlich's idea."
        }
    },
    {
        "utterance": "Chris Whidbey: So if I'm ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey: looking through I feel like I can clump things into different categories and please let me know if I missing anything. I think that's another system then we can add the circadian circuitry. As far as kind of detection methods ",
        "annotations": {
            "develop idea": "The speaker is suggesting a way to organize information into categories and mentioning a potential new system (circadian circuitry), which involves building on existing concepts.",
            "encourage participation": "The speaker asks for feedback ('please let me know if I missing anything'), inviting others to contribute."
        }
    },
    {
        "utterance": "Chris Whidbey: So it seems like exist or can be developed but you'd have to know what you're trying to do that first step. Um so that seems like that's kind of one bottleneck is dealing with all of the unknown ",
        "annotations": {
            "identify gap": "Chris identifies dealing with unknowns as a significant bottleneck in method development.",
            "offer feedback": "Chris provides an analysis on the necessity of knowing what you're trying to do as a first step in method development, which serves as feedback."
        }
    },
    {
        "utterance": "Chris Whidbey: I was going to say I I summarized the best that I could but I uh ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: That's that's a great job. ",
        "annotations": {
            "Acknowledge contribution": "The speaker verbally recognizes another group member's input.",
            "Supportive response": "The speaker expresses agreement or positive evaluation for another group member's contribution."
        }
    },
    {
        "utterance": "Chris Whidbey: I was going to say I I summarized the best that I could but I uh ",
        "annotations": {
            "acknowledge contribution": "Chris Whidbey acknowledges his effort to summarize.",
            "supportive response": "Chris Whidbey's comment comes across as humble and positive about his summarizing effort."
        }
    },
    {
        "utterance": "Chris Whidbey: I'm going to share screen on it. ",
        "annotations": {
            "process management": "Chris Whidbey is managing the meeting flow by preparing to share his screen."
        }
    },
    {
        "utterance": "Aida Ebrahimi: I'm going to say. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: So the there is just a note from uh Andrew that we should try to kind of summarize our key things and I think our aim is to eventually have like one slide with some of the key questions that we discussed. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing what has been previously discussed about the aim to have one slide with key questions.",
            "process management": "The speaker is managing the meeting flow by suggesting a summary of key points."
        }
    },
    {
        "utterance": "Aida Ebrahimi: you think we can ",
        "annotations": {
            "ask question": "The utterance is structured as a question, seeking clarification or agreement on something."
        }
    },
    {
        "utterance": "Amina Schartup: Well I if I can jump in, I mean, to me as someone who like, you know, this discussion is really, really interesting. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey: What are your questions? ",
        "annotations": {
            "ask question": "The speaker is requesting information or questions from others.",
            "encourage participation": "The speaker is inviting others to contribute their questions or thoughts."
        }
    },
    {
        "utterance": "Amina Schartup: I think I think for me the big themes that came out of it were that I mean what isn't? I thought that was a really interesting question. You know, like what isn't? And that this um you know, this whole idea of the systems is is very, very complex. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing the big themes that came out of the discussion."
        }
    },
    {
        "utterance": "Barbara Bendlin: Sorry, I was on mute. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: I was wondering if anyone um could be willing to um work with Chris maybe to um just bring up the PowerPoint. We can start putting our um thoughts into the um PowerPoint. So kind of like a co-reporter role. ",
        "annotations": {
            "assign task": "Barbara Bendlin is assigning a task to someone to work with Chris on the PowerPoint.",
            "process management": "Barbara Bendlin is managing the meeting flow and organizing group activities by suggesting a co-reporter role."
        }
    },
    {
        "utterance": "Chris Whidbey: Are you okay transcribing our ",
        "annotations": {
            "ask question": "Chris Whidbey is requesting confirmation about transcribing their conversation."
        }
    },
    {
        "utterance": "Barbara Bendlin: Yes. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement with a previous statement."
        }
    },
    {
        "utterance": "Chris Whidbey: I'm happy to. ",
        "annotations": {
            "supportive response": "The speaker expresses willingness to help with a task, showing a positive and cooperative attitude."
        }
    },
    {
        "utterance": "Barbara Bendlin: So that's good. If you're if you're okay typing in into the into the PowerPoint then we can we can let you in as a co-reporter. ",
        "annotations": {
            "process management": "Barbara Bendlin is managing the meeting flow by discussing and organizing roles and tasks.",
            "assign task": "Barbara Bendlin is assigning a task (transcribing into PowerPoint) and a role (co-reporter) to Chris Whidbey."
        }
    },
    {
        "utterance": "Chris Whidbey: I think about Wiki gut and microbiome um pages is interesting right and then ties into the vasculature. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing thought by relating different concepts (Wiki gut and microbiome pages to vasculature)."
        }
    },
    {
        "utterance": "Chris Whidbey: summarize ",
        "annotations": {
            "summarize conversation": "The speaker is requesting a summary of what has been discussed previously in the meeting."
        }
    },
    {
        "utterance": "Aida Ebrahimi: species identification. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Unknown speaker: Do you want to repeat it all again? I can like type fast. ",
        "annotations": {
            "process management": "The speaker is offering to facilitate the meeting process by repeating what was discussed and typing quickly to help with notes or summaries."
        }
    },
    {
        "utterance": "Aida Ebrahimi: Yeah, yeah. It's just a speech that I've had prepared all morning actually. There are a lot of data that already exist out there. Um, so, um, AI needs the data and I think there are a lot of data that are out there. So some data mining, it's not my expertise but I'm sure we have some people that work on these. And that they can mine the data, existing data. Um, there are a lot of reports that they I was actually looking at some review papers like studying germ free um mice and then uh uh some specific SPF mice. So uh those data are out there. So maybe that's one way to mind the mind those data. That the biomarker or species that are involved in these I don't know mechanisms. So the gut metabolome way or anything is to induce. ",
        "annotations": {
            "propose new idea": "The speaker introduces the idea of using data mining to find biomarkers or species involved in certain mechanisms.",
            "develop idea": "The speaker is expanding on existing ideas by suggesting data mining as a method to find relevant data for their research."
        }
    },
    {
        "utterance": "Unknown speaker: So uh you know, I think we got ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Aida Ebrahimi: Chris, do you think the one the what you, you know, we if we want to copy what Chris wrote down and divide it between among these three. So uh how they are relevant to these. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification from Chris regarding how to organize or divide information that Chris previously mentioned."
        }
    },
    {
        "utterance": "Unknown speaker: I'm glad I'm not supposed to paper so discussion in three minutes. ",
        "annotations": {
            "process management": "The speaker is concerned about the time constraint for summarizing the discussion, indicating a focus on managing meeting flow."
        }
    },
    {
        "utterance": "Unknown speaker: Uh, not really. Thank you for asking. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Yanjiao Zhou: So, so I do feel in the first part of this discussion when we talk about all the different organisms. ",
        "annotations": {
            "summarize conversation": "The speaker is reflecting on the first part of the discussion, mentioning the topic of different organisms, which indicates summarizing previous conversation content."
        }
    },
    {
        "utterance": "Yanjiao Zhou: Um are also very interesting so because all those I guess. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey: I didn't understand as much about understanding as much about that. So maybe just in the end also adding all the summary of all the key phrases. Just it's already although I think that would be very informative for most of the discussion. I don't know if somebody a little more versed than that wanted to summarize. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges the discussion's complexity and suggests a way to summarize key points, showing awareness of others' contributions.",
            "supportive response": "The speaker expresses a desire to understand and suggests summarizing key phrases to aid the discussion, showing a supportive attitude."
        }
    },
    {
        "utterance": "Aida Ebrahimi: I don't know how to summarize it too. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it is a simple expression of inability to summarize."
        }
    },
    {
        "utterance": "Aida Ebrahimi: Chris, would you just a couple of keywords? Are we going to um divide them into three pieces and barely are relevant, right? I don't know what to right. Am I right or no? I I understood it. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification from another group member.",
            "clarify goal": "The speaker is seeking to understand the goal or method of organizing information."
        }
    },
    {
        "utterance": "Chris Whidbey: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Aida Ebrahimi: I think that was detection technology. inflammation and immune responses uh affecting. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing or reflecting on previous discussion points regarding detection technology, inflammation, and immune responses."
        }
    },
    {
        "utterance": "Aida Ebrahimi: Really if we identify, so maybe it's a separate thing by itself. If we identify what are those uh biomarkers or species, then we can think about building diagnostics or sensors in for real time analysis or in situ analysis for them. I think that's actually what I heard was that there was really a mixture of in vitro um in vivo models. Um Ashley's looking at intestinal tissue um and then working your way up also, you know, you have controlled germ free animals, then you can also look at humans with and without disease, right? So healthy or with disease. I think they're all important, no? I mean absolutely. And I heard everyone sort of dismissing. So this particular thing I'm highlighting about the sort of dynamics of within the microbiome and the interactions between them. And I wonder just from a straight medicine perspective. And what I heard was that there was really a mixture of in vitro in vivo models. Ashley's looking at intestinal tissue and then working your way up also, you know, you have controlled germ free animals, then you can also look at humans with and without disease, right? So healthy or with disease. I think they're all important, no? I mean absolutely. And I heard everyone sort of dismissing. So this particular thing I'm highlighting about the sort of dynamics of within the microbiome and the interactions between them. And I wonder just from a straight medicine perspective. They can be tools that can be used to monitor different that we haven't complete understanding of and that textbook definition. ",
        "annotations": {
            "propose new idea": "Aida Ebrahimi suggests identifying biomarkers or species to develop diagnostics or sensors.",
            "develop idea": "She elaborates on her idea by mentioning the use of in vitro and in vivo models.",
            "ask question": "Aida Ebrahimi wonders about the dynamics within the microbiome and interactions from a medicine perspective."
        }
    },
    {
        "utterance": "Aida Ebrahimi: One third changes for example, by change I mean if we want to go with the route that we are co-culturing in vitro two different species for example. And we want to study the effect of if we are changing I don't know hormone concentration um in that model. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an idea by providing a concrete example of how changes could be studied.",
            "offer feedback": "The speaker provides a suggestion or example on how to approach studying changes, which can be seen as offering feedback."
        }
    },
    {
        "utterance": "Aida Ebrahimi: It could be in vitro or in vivo like mouse model. So whatever that design is, then we have to have some path to be able to at least that is um one of what one of the things that we discussed is in real time monitor level of those small molecules or those biomarkers in real time without the need to kill them or slice the tissue things like that which is really totally different. Of course those approaches are needed as a standard to compare with. But if we want to see in real time what is going on then those sensors can be integrated or embedded in that in vitro or in vivo model. Of course it needs to make sure for being more complex but there are in my opinion that's what I think you have to have access to all those genomics metabolomics all the omics. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of monitoring small molecules or biomarkers in real-time and discussing the approaches for doing so.",
            "offer feedback": "The speaker is providing suggestions for how to approach the problem of real-time monitoring.",
            "identify gap": "The speaker implies a gap in current methods, specifically the need for real-time monitoring without destructive sampling."
        }
    },
    {
        "utterance": "Aida Ebrahimi: What was that sorry? ",
        "annotations": {
            "ask question": "Aida Ebrahimi is requesting information or clarification about something previously said."
        }
    },
    {
        "utterance": "Erin Longbrake: Sorry need to. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Aida Ebrahimi: Sorry. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: So the overall problem of how do we model specific metabolites kind of one at a time or. What's the limits of the platform? How how multiplex does it get? Yeah, that's a really good point instead of just what the the sort of static microbiome levels are and what are the dynamics of the interactions between them. ",
        "annotations": {
            "develop idea": "expanding on the idea of modeling metabolites and considering platform capabilities",
            "ask question": "inquiring about the limits and multiplex capabilities of the platform",
            "offer feedback": "highlighting the importance of dynamics of interactions beyond static microbiome levels"
        }
    },
    {
        "utterance": "Aida Ebrahimi: They do, right? ",
        "annotations": {
            "Supportive response": "The speaker is seeking agreement, which is a way of expressing validation or positive evaluation for a prior statement."
        }
    },
    {
        "utterance": "Aida Ebrahimi: Norepinephrine serotonin glutamate. There are studies that they showed they definitely relationship. ",
        "annotations": {
            "develop idea": "Aida Ebrahimi is expanding on the topic by mentioning specific substances (norepinephrine, serotonin, glutamate) and their relationships as studied, thereby developing the idea through referencing existing research."
        }
    },
    {
        "utterance": "Unknown speaker: You know, let me add there's a spatial component too. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new aspect to consider in the discussion, mentioning a spatial component that has not been previously discussed."
        }
    },
    {
        "utterance": "Aida Ebrahimi: What else is there? ",
        "annotations": {
            "ask question": "The speaker is requesting additional information or suggestions, indicating a need for more details or ideas."
        }
    },
    {
        "utterance": "Aida Ebrahimi: There are studies that they showed they definitely relationship. I think you mentioned also some actually. I think you're mentioning about the small intestines. Yeah, yeah, glutamate is that norepinephrine serotonin dopamine uh what else do we have? Some like neurochemicals or you know hormones. Well, I can I can see the the discussion is kind of winding down and that's that's good. I I really enjoyed this guys. Um all the different inputs. Um ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by mentioning specific substances like glutamate, norepinephrine, serotonin, and dopamine.",
            "acknowledge contribution": "The speaker acknowledges the discussion and the inputs from others, showing appreciation for the contributions made."
        }
    },
    {
        "utterance": "Barbara Bendlin: And what I heard was that there was really a a mixture of in vitro um in vivo models. Um Ashley's looking at intestinal tissue um and then working your way up also, you know, you have controlled germ free animals, then you can also look at humans with and without disease, right? So healthy or with disease. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing previous discussion points regarding the mixture of in vitro and in vivo models used in research, including the use of controlled germ-free animals and humans with and without disease."
        }
    },
    {
        "utterance": "Aida Ebrahimi: I think they're all important, no? ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement and validation for others' contributions without adding new content."
        }
    },
    {
        "utterance": "Barbara Bendlin: Absolutely. and I heard everyone sort of dismissing. ",
        "annotations": {
            "supportive response": "The speaker expresses agreement and acknowledges others' perspectives."
        }
    },
    {
        "utterance": "Unknown speaker: Yeah, so ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Aida Ebrahimi: In terms of humans. I mean I was reading papers it seems like the patients like really like clinical experiments. There are already a lot of like mass spec data that people that they are part of these studies, the data is available. So um ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Unknown speaker: So all of these questions relate to right. ",
        "annotations": {
            "summarize conversation": "The speaker is attempting to relate or summarize how various questions pertain to the current topic or discussion point."
        }
    },
    {
        "utterance": "Aida Ebrahimi: Yeah, yeah. glutamate is that norepinephrine serotonin dopamine uh what else do we have? ",
        "annotations": {
            "ask question": "Aida Ebrahimi is requesting information on additional metabolites or neurotransmitters beyond glutamate, norepinephrine, serotonin, and dopamine."
        }
    },
    {
        "utterance": "Unknown speaker: You know, let me add there's a spatial component too. ",
        "annotations": {
            "propose new idea": "The utterance adds a new perspective to the discussion, which can be seen as proposing a new idea for consideration."
        }
    },
    {
        "utterance": "Aida Ebrahimi: There are studies that they showed they definitely relationship. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges the existence of studies that have shown a relationship, thereby recognizing others' contributions."
        }
    },
    {
        "utterance": "Unknown speaker: As a matter of fact, all the studies I've done finds the information after stroke with hypertension or small vessel disease, it all seems to be in the small intestines yet. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: So if you want to if you want to add a few comments and if others want to help Chris with the second two. ",
        "annotations": {
            "encourage participation": "Erin Longbrake invites others to contribute comments and help Chris with tasks.",
            "process management": "Erin Longbrake is managing the discussion flow by suggesting how others can assist with reporting tasks."
        }
    },
    {
        "utterance": "Aida Ebrahimi: you know, correlation. It's not causal, not so much as what as I know. I think there is you don't have causal information like what is exactly going on. That's one of the big big issues, right? ",
        "annotations": {
            "identify gap": "The speaker highlights a significant gap in current research: the inability to determine causal relationships.",
            "critical response": "The speaker critiques current research by emphasizing the limitation that correlation does not imply causation."
        }
    },
    {
        "utterance": "Erin Longbrake: What kind of tools do we mean and how can we make sure you have the right expertise to build them. ",
        "annotations": {
            "ask question": "The speaker is requesting information about the tools and expertise needed, directly asking for clarification.",
            "identify gap": "The speaker implies a current lack of certain tools or expertise, indicating a gap."
        }
    },
    {
        "utterance": "Erin Longbrake: My internet has been wonky. I'll try to see if I can get it more reliable over the next. ",
        "annotations": {
            "process management": "The speaker mentions a technical issue with their internet connection and plans to resolve it, which relates to managing their participation in the meeting."
        }
    },
    {
        "utterance": "Aida Ebrahimi: We also talked about um you talked about niche like um an easy digestible review. ",
        "annotations": {
            "summarize conversation": "The speaker is attempting to recall and summarize previous discussion points."
        }
    },
    {
        "utterance": "Flavio Frohlich: Well, I think at multiple levels, but uh the the original thought I I proposed to the group I believe was that if we have um uh these assets, we need to be strategist by now to develop models of the interaction and kind of the the maybe grouping or clustering of um let's say envision metabolites or whatever whatever level of analysis we're choosing. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing idea about the need to develop models for understanding interactions between different elements, such as metabolites, at various levels of analysis."
        }
    },
    {
        "utterance": "Andrew Feig: I tell you what, I just dropped in the resource like I think uh yeah, I did. It's group 1.2 system level. You know, a couple days ago or maybe it was even yesterday. I just I just put a few key terms in and pulled up some papers. Some I I haven't read any of them. I shouldn't say that. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it primarily involves sharing resources without explicitly matching any provided code description."
        }
    },
    {
        "utterance": "Mei Shen: So I see how also I should mention about the back here. So do you already include that or? ",
        "annotations": {
            "ask question": "The speaker is requesting information about the inclusion of something in a document or presentation."
        }
    },
    {
        "utterance": "Shikha Nangia: Yeah, I don't see the way I was describing it, but that was like sort of a thought experiment to start with uh mice with no uh microbiota but progressively introduce complexity. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges her previous contribution by referring back to it.",
            "develop idea": "The speaker develops her idea by providing more details about the thought experiment."
        }
    },
    {
        "utterance": "Barbara Bendlin: Could you add 4.1? Um the idea being start with germ free mice at microbiota and do metabolomics. ",
        "annotations": {
            "propose new idea": "The speaker is introducing a new experimental approach involving starting with germ-free mice and doing metabolomics."
        }
    },
    {
        "utterance": "Andrew Feig: Well, you know, another aspect of that that I'm worried about. And that is there's some tools out there that I don't know about. And you know, they're new tools and that's the reason and uh. ",
        "annotations": {
            "identify gap": "The speaker is expressing concern about not knowing about new tools that might be available, indicating a gap in his knowledge."
        }
    },
    {
        "utterance": "Andrew Feig: I I think it's just fascinating that I stumble on this. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: And then bringing the data science and machine learning into the process. ",
        "annotations": {
            "clarify goal": "Defining, clarifying, or seeking clarity on objectives, outcomes, expectations, or success criteria for the group to achieve.",
            "supportive response": "Expressing agreement, validation, or positive evaluation for other group members' contributions without adding new content."
        }
    },
    {
        "utterance": "Andrew Feig: Yeah, that you know in principle, right? ",
        "annotations": {
            "None": "The utterance is a minimal response that doesn't explicitly fit into any of the provided codes but can be seen as a weak form of acknowledgment or agreement."
        }
    },
    {
        "utterance": "Barbara Bendlin: It sounds from that like you could imagine like a workshop where people just like present all the tools that they that are available and other scientists could go and and sort of find the things that are most relevant. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new idea about organizing a workshop for sharing tools among researchers.",
            "process management": "The suggestion of a workshop is related to managing group activities and facilitating collaboration."
        }
    },
    {
        "utterance": "Shikha Nangia: So I'm trying to see within the group if there is some some correlation around the topic that we can think of. I totally agree that a bigger group is also um explaining from the science end like what specific thing is needed. ",
        "annotations": {
            "supportive response": "The speaker expresses agreement with the potential benefits of a larger group in explaining scientific aspects.",
            "encourage participation": "The speaker is engaging with the group to find common themes or correlations.",
            "clarify goal": "The speaker is trying to understand the group's discussion and goals better."
        }
    },
    {
        "utterance": "Aida Ebrahimi: I think the goal would be all the different groups they report out then it it is a there will be okay, some thinking by by people then just reaching out to each other. Maybe this group, I don't know, like just among uh group 11. But I think that's not what what Andrew said. ",
        "annotations": {
            "Develop idea": "The speaker is reflecting and possibly expanding on a previously mentioned idea about group reporting.",
            "Ask question": "The speaker is seeking clarification or confirmation regarding the goal or process.",
            "Process management": "The speaker is discussing the process of how groups should interact or report."
        }
    },
    {
        "utterance": "Barbara Bendlin: You can start thinking about it. So that not necessarily this group will be like a final research group, but you know, think about who you met here today and you can reach out to whose research, you know, sounds like it might mesh with some of your ideas and then you'll be able to reach out to one another to form these teams. ",
        "annotations": {
            "Develop idea": "The speaker develops the idea of considering future collaborations by suggesting that participants think about whose research aligns with theirs.",
            "Encourage participation": "The utterance encourages participants to reach out to one another to form teams based on common research interests.",
            "Process management": "The speaker manages the process by suggesting how to think about and potentially form research teams."
        }
    },
    {
        "utterance": "Shikha Nangia: Yeah, I think trying to see within the group if there is some some correlation around the topic that we can think of. I totally agree that a bigger group is also. ",
        "annotations": {
            "supportive response": "The utterance expresses agreement and a positive evaluation of the idea.",
            "acknowledge contribution": "Shikha is acknowledging the idea and suggesting a bigger group could be beneficial."
        }
    },
    {
        "utterance": "Andrew Feig: part of the assessment of the Syllog program at large. So um uh they are actually recording the sessions. This is something I'll just say while we're waiting for everyone to be back in the room. One of the things we do is is a study of how new collaborations form and what happens at the meetings that help to lead that so that we can adjust the nature of the meeting. ",
        "annotations": {
            "process management": "The speaker is discussing the study of how new collaborations form and how meetings help lead to that, in order to adjust the nature of the meeting."
        }
    },
    {
        "utterance": "Andrew Feig: Um and so we have data now 10 years running on. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it seems to be a statement of fact providing background information."
        }
    }
]